ATI-2231 in Advanced Solid Tumor Malignancies

A Phase Ia Trial of ATI-2231 in Advanced Solid Tumor Malignancies

The purpose of this first-in-human study is to test ATI-2231 in advanced solid tumor malignancies with the goal of establishing the recommended Phase II dose of ATI-2231.

Study Overview

• Status: Withdrawn
• Conditions: Advanced Solid Tumor; Advanced Solid Tumor Malignancies
• Intervention / Treatment: Drug: ATI-2231

• Study Type: Interventional
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Cynthia X Ma, M.D, Ph.D.; Phone Number: 314-362-8903; Email: cynthiaxma@wustl.edu
• Study Contact Backup: Name: Katherine Clifton, M.D.; Phone Number: 314-273-3712; Email: k.clifton@wustl.edu

Study Locations

• United States
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University School of Medicine
      • Contact: Katherine Clifton, M.D.; Phone Number: 314-273-3712; Email: k.clifton@wustl.edu
      • Contact: Cynthia X Ma, M.D., Ph.D.; Phone Number: 314-362-8903; Email: cynthiaxma@wustl.edu
      • Principal Investigator: Cynthia X Ma, M.D., Ph.D.
      • Sub-Investigator: Sheila Stewart, Ph.D.
      • Sub-Investigator: Roberto Civitelli, M.D.
      • Sub-Investigator: Stefanie Geisler, M.D.
      • Sub-Investigator: Jingqin (Rosy) Luo, Ph.D.
      • Sub-Investigator: Katherine Clifton, M.D.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Biopsy-proven advanced solid tumor malignancy including head and neck cancer, non-small cell lung cancer, gastrointestinal adenocarcinoma, pancreatic adenocarcinoma, prostate cancer, bladder cancer, and breast cancer.
• Eligible patients must have an advanced solid malignancy above, for which standard curative or palliative therapies do not exist or are no longer effective.
• Measurable or non-measurable but evaluable disease by RECIST v 1.1.
• Patients must have archival tissue sample available from prior metastatic biopsy. If no tissue is available, patient may still be able to enroll with PI approval.
• At least 18 years of age.
• ECOG performance status ≤ 2
• Life expectancy of at least 12 weeks.

• Adequate bone marrow and organ function as defined below:

  • Leukocytes ≥ 3 K/cumm
  • Absolute neutrophil count (ANC) ≥ 1.5 K/cumm
  • Platelets ≥ 100 K/cumm
  • Total bilirubin ≤ 1.5 x IULN (unless patient has known Gilberts disease)
  • AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
  • Creatinine clearance > 60 mL/min by Cockcroft-Gault
• The effects of ATI-2231on the developing human fetus are unknown. For this reason, women of childbearing potential and men who are heterosexually active must agree to use adequate contraception as specified in the protocol. Contraception should continue for 1 month (for women) or 3 months (for men) after the end of treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
• Ability to understand and willingness to sign an IRB approved written informed consent document.

Exclusion Criteria:

• Patients may not have received the following investigational or SOC therapies within the below specified time frames prior to C1D1:

  • Denosumab or bisphosphonates within 4 weeks
  • Radiation therapy within 1 week
  • Systemic chemotherapy, including antibody drug conjugates with chemotherapy payload, within 3 weeks.
  • Immunotherapy within 3 weeks
  • Oral chemotherapy or molecularly targeted therapy within 5 half-lives of the agent.
  • Endocrine therapies do not have a required washout and may be continued until C1D1.
• Untreated brain metastases. Patients with treated brain metastases are eligible if they show no evidence of progression and are off steroids or on stable/decreasing steroid dose.
• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to ATI-2231.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
• Patients with known HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.
• Screening resting QTcF above 460 ms (average of triplicate).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ATI-2231 monotherapy dose escalation; Patients will receive single agent ATI-2231 at assigned dose levels (n=3-6 per dose level). Starting dose of 20 mg by mouth twice per day.; Each cycle is 21 days	Drug: ATI-2231; Provided by Aclaris Therapeutics, Inc.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants experiencing adverse events	-Graded per CTCAE v. 5.0	From baseline through 30 days after end of treatment (estimated to be 7 months)

Secondary Outcome Measures

Outcome Measure	Time Frame
Changes in ATI-2231 pharmacokinetics (PK) as measured by time to peak drug concentration (Tmax)	Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)
Changes in ATI-2231 pharmacokinetics (PK) as measured by elimination rate constant	Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)
Changes in ATI-2231 pharmacokinetics (PK) as measured by apparent volume of distribution	Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)
Changes in ATI-2231 pharmacokinetics (PK) as measured by apparent clearance	Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)
Changes in ATI-2231 pharmacokinetics (PK) as measured by peak concentration (Cmax)	Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)
Changes in ATI-2231 pharmacokinetics (PK) as measured by half-life (T1/2)	Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 (estimated to be 2 days)
Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-24h)	Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, and 24 hours post dose cycle 1 (estimated to be 1 day)
Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-infinity)	Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 (estimated to be 2 days)
Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-t)	Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 (estimated to be 2 days)
Changes in ATI-2231 pharmacokinetics (PK) as measured by peak concentration (Cmax)	Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours)
Changes in ATI-2231 pharmacokinetics (PK) as measured by trough concentration	Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours)
Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-t)	Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours)
Changes in ATI-2231 pharmacokinetics (PK) as measured by time to peak drug concentration (Tmax)	Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours)
ATI-2231 pharmacokinetics (PK) as measured by trough concentration	Cycle 3 day 1 (each cycle is 21 days)
ATI-2231 pharmacokinetics (PK) as measured by trough concentration	Cycle 4 day 1 (each cycle is 21 days)
ATI-2231 pharmacokinetics (PK) as measured by trough concentration	Cycle 5 day 1 (each cycle is 21 days)
ATI-2231 pharmacokinetics (PK) as measured by trough concentration	Cycle 6 day 1 (each cycle is 21 days)

Collaborators and Investigators

• Sponsor: Washington University School of Medicine
• Collaborators: Aclaris Therapeutics, Inc.
• Investigators: Principal Investigator: Cynthia X Ma, M.D., Ph.D., Washington University School of Medicine

Publications and helpful links

Helpful Links

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Study record dates

Study Major Dates

• Study Start (Actual): November 15, 2023
• Primary Completion (Estimated): June 30, 2025
• Study Completion (Estimated): June 30, 2025

Study Registration Dates

• First Submitted: January 31, 2023
• First Submitted That Met QC Criteria: March 16, 2023
• First Posted (Actual): March 30, 2023

Study Record Updates

• Last Update Posted (Actual): November 29, 2023
• Last Update Submitted That Met QC Criteria: November 28, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: MK2 inhibitor; ATI-2231
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bone Density Conservation Agents; Capecitabine; Denosumab; Diphosphonates
• Other Study ID Numbers: 202306048

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Individual patient data may be shared upon request with other non-commercial researchers and the request will be reviewed by the study team after the publication.
• IPD Sharing Time Frame: After the publication
• IPD Sharing Access Criteria: Please email cynthiaxma@wustl.edu for requests.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No